Treatment Options in HER2+ eBC Breast Cancer

 

Dana-Farber Cancer Institute
A

Updates on the Personalized Management of HER2+ eBC for 2023

By Dana-Farber Cancer Institute FEATURING Adrienne Waks
By Dana-Farber Cancer Institute FEATURING Adrienne Waks
81 views
May 31, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Options in HER2+ eBC Breast Cancer
06:04
Scripps MD Anderson Cancer Center

Treatment Approaches of HER2+ mBC

Feat. J. Mortimer
14:20
OncoAlert

Anti-HER2 (non-ADC) Therapy in Treatment of HER2+- BC: Current Clini…

Feat. C. Saura
30:56
Houston Methodist Hospital

Biology-Driven De-Escalation of Therapy in HER2+ BC

Feat. P. Niravath
06:40
Parvin Peddi

Pertuzumab & Trastuzumab in HER2+ BC: IV vs. SQ Administration, …

12:38
OncoAlert

Anti-HER2 (non-ADC) Therapy in Treatment of HER2+- BC: Integration W…

Feat. S. Alkner
10:54
Yale Cancer Center

De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers

Feat. L. Pusztai
04:10
ecancer

ASCO® 2023 Insights: "PHERGain Data on Dual HER2 Blockade Witho…

Feat. J. Cortes
13:15
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Biomarkers Predicting Response to 5 IO Ar…

Feat. D. Wolf
28:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
11:13
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Are We Splitting HERs? The Highs and Lows…

Feat. D. Rimm
20:09
2023 Best of Breast Conference

Optimizing Treatment in Early Stage HER2+ BC

Feat. R. L. Mahtani
15:18
OncoAlert

Early HR+/HER2+ BC Updates

Feat. E. de Azambuja
11:01
Dana-Farber Cancer Institute

Updates on the Personalized Management of HER2+ eBC for 2023

Feat. A. Waks